CGS 24128
Latest Information Update: 22 May 2001
Price :
$50 *
At a glance
- Originator Novartis
- Class Antihypertensives
- Mechanism of Action Endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 22 May 2001 No-Development-Reported for Hypertension in USA (IV)
- 02 Jul 1997 Preclinical development for Hypertension in USA (IV)